BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise

Reuters

May 15, 2025

BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise

** BTIG starts coverage on Tvardi Therapeutics TVRD.O with "buy" rating and $55 PT, 108.7% upside to stock's last close

** Brokerage says TVRD is "presumptive first mover" in developing STAT3 inhibitors for fibrotic diseases, targeting previously "undruggable" protein with "highly validated and well-characterized" profile

** Fibrotic diseases are type of lung illnesses

** Co's lead drug, TTI-101, has potential to be "breakthrough therapy" that can actually reverse these diseases, rather than just slowing their progression, BTIG says

** Says early results from clinical trial are "unusually persuasive", with over 50% of patients showing improvement - outcome that is "unlikely without an active therapy"

** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says

** As of last close, stock up 43.5% YTD

(Reporting by Kamal Choudhury in Bengaluru)

((Kamal.Choudhury@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2535846417"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2535846417\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2535846417?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-05-15 19:18","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2535846417","market":"us","top_or_hot":-1,"title":"BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise </title></head><body><p>** BTIG starts coverage on Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>TVRD.O</span> with \"buy\" rating and $55 PT, 108.7% upside to stock's last close</p><p>** Brokerage says TVRD is \"presumptive first mover\" in developing STAT3 inhibitors for fibrotic diseases, targeting previously \"undruggable\" protein with \"highly validated and well-characterized\" profile</p><p>** Fibrotic diseases are type of lung illnesses</p><p>** Co's lead drug, TTI-101, has potential to be \"breakthrough therapy\" that can actually reverse these diseases, rather than just slowing their progression, BTIG says</p><p>** Says early results from clinical trial are \"unusually persuasive\", with over 50% of patients showing improvement - outcome that is \"unlikely without an active therapy\"</p><p>** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says</p><p>** As of last close, stock up 43.5% YTD</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-05-15 19:18</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise </title></head><body><p>** BTIG starts coverage on Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> <span>TVRD.O</span> with \"buy\" rating and $55 PT, 108.7% upside to stock's last close</p><p>** Brokerage says TVRD is \"presumptive first mover\" in developing STAT3 inhibitors for fibrotic diseases, targeting previously \"undruggable\" protein with \"highly validated and well-characterized\" profile</p><p>** Fibrotic diseases are type of lung illnesses</p><p>** Co's lead drug, TTI-101, has potential to be \"breakthrough therapy\" that can actually reverse these diseases, rather than just slowing their progression, BTIG says</p><p>** Says early results from clinical trial are \"unusually persuasive\", with over 50% of patients showing improvement - outcome that is \"unlikely without an active therapy\"</p><p>** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says</p><p>** As of last close, stock up 43.5% YTD</p><p> (Reporting by Kamal Choudhury in Bengaluru)</p><p> ((Kamal.Choudhury@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVRD","symbol_name":"Tvardi Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250515:nL4N3RN0XG:1","article_id":"2535846417","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2535846417","pubTimestamp":1747307890,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise ** BTIG starts coverage on Tvardi Therapeutics TVRD.O with \"buy\" rating and $55 PT, 108.7% upside to stock's last close** Brokerage says TVRD is \"presumptive first mover\" in developing STAT3 inhibitors for fibrotic diseases, targeting previously \"undruggable\" protein with \"highly validated and well-characterized\" profile** Fibrotic diseases are type of lung illnesses** Co's lead drug, TTI-101, has potential to be \"breakthrough therapy\" that can actually reverse these diseases, rather than just slowing their progression, BTIG says** Says early results from clinical trial are \"unusually persuasive\", with over 50% of patients showing improvement - outcome that is \"unlikely without an active therapy\"** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says** As of last close, stock up 43.5% YTD  ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVRD":"Tvardi Therapeutics Inc","BK4007":"制药"},"translate_title":"BUZZ-BTIG以“买入”开始报道Tvardi，因为co的逆转肺部疤痕的药物显示出希望","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVRD":0.9},"content_text":"BUZZ-BTIG starts Tvardi's coverage with 'buy' as co's drug to reverse lung scarring shows promise ** BTIG starts coverage on Tvardi Therapeutics TVRD.O with \"buy\" rating and $55 PT, 108.7% upside to stock's last close** Brokerage says TVRD is \"presumptive first mover\" in developing STAT3 inhibitors for fibrotic diseases, targeting previously \"undruggable\" protein with \"highly validated and well-characterized\" profile** Fibrotic diseases are type of lung illnesses** Co's lead drug, TTI-101, has potential to be \"breakthrough therapy\" that can actually reverse these diseases, rather than just slowing their progression, BTIG says** Says early results from clinical trial are \"unusually persuasive\", with over 50% of patients showing improvement - outcome that is \"unlikely without an active therapy\"** Upcoming mid-stage trial data expected in 2H25 could be major catalyst for stock, BTIG says** As of last close, stock up 43.5% YTD (Reporting by Kamal Choudhury in Bengaluru) ((Kamal.Choudhury@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}